Because CYP26C1 catalyzes the degradation of all-trans RA, these studies suggest the hypothesis that variation in CYP26C1 activity and epigenetic chromosomal changes in CYP26C1, which affect the mRNA expression of CYP26C1, might be associated with stroke. This evidence concerns the gene CYP26C1 and Stroke.